Xylyx Bio
Xylyx Bio is dedicated to transforming regenerative medicine through bioengineering, with a focus on bioengineered human organs and extracellular matrix technologies. Their mission is to save lives by significantly increasing the availability of human organs for transplantation, utilizing innovative platforms like xenogeneic cross-circulation to develop fully functional, anatomically compatible organ grafts. They are committed to pioneering solutions for organ shortages, advancing tissue regeneration, and improving clinical outcomes through their cutting-edge research, products, and collaborations.
Industries
Nr. of Employees
small (1-50)
Xylyx Bio
760 Parkside Avenue, Brooklyn, NY 11226
Products
Tissue-specific dECM coating and hydrogel kits
Ready-to-use, quality-controlled decellularized ECM kits processed into coatings and hydrogels for tissue-specific in vitro culture and disease modeling.
Assay kits for disease modeling (IPF, NASH, metastasis)
Assays and kits designed to model specific disease states (e.g., human IPF, NASH) and metastatic microenvironments using tissue-specific ECM substrates.
Bioactive ECM-derived peptide formulations
Combinations of ECM-derived matrikine peptides developed to activate regenerative pathways and modulate inflammation for tissue repair; evaluated in topical applications and clinical studies.
Tissue-specific dECM coating and hydrogel kits
Ready-to-use, quality-controlled decellularized ECM kits processed into coatings and hydrogels for tissue-specific in vitro culture and disease modeling.
Assay kits for disease modeling (IPF, NASH, metastasis)
Assays and kits designed to model specific disease states (e.g., human IPF, NASH) and metastatic microenvironments using tissue-specific ECM substrates.
Bioactive ECM-derived peptide formulations
Combinations of ECM-derived matrikine peptides developed to activate regenerative pathways and modulate inflammation for tissue repair; evaluated in topical applications and clinical studies.
Services
Ex vivo rehabilitation of donor organs using xenogeneic cross-circulation and normothermic physiologic support to restore organ function prior to transplantation.
Collaborative research and licensing partnerships with academic laboratories and clinical investigators to advance organ rehabilitation methods and translational studies.
Ex vivo rehabilitation of donor organs using xenogeneic cross-circulation and normothermic physiologic support to restore organ function prior to transplantation.
Collaborative research and licensing partnerships with academic laboratories and clinical investigators to advance organ rehabilitation methods and translational studies.
Expertise Areas
- Organ bioengineering and ex vivo organ rehabilitation
- Decellularized extracellular matrix biomaterials
- Disease-relevant in vitro models and assay development
- Peptide-based regenerative therapeutics
Key Technologies
- Xenogeneic cross-circulation (porcine bioreactor) for ex vivo support
- Normothermic extracorporeal organ perfusion
- Tissue-specific decellularized ECM hydrogels and coatings
- Matrikine peptide combinations (bioactive ECM-derived peptides)
News & Updates
Research on lung rehabilitation using xenogeneic cross-circulation platform, demonstrating no hyperacute rejection in a human lung transplantation model.
Development of a theranostic approach for ex vivo donor lung rehabilitation leveraging xenogeneic cross-circulation.
Funding received to support the development and clinical translation of bioengineered organs.
The company received a significant grant to advance treatments for fibrotic liver disease.
Funding to support research in cancer treatment applications.
Recognized for creating a new ingredient/technology or innovative use of an existing one in cosmetic products.
Research on lung rehabilitation using xenogeneic cross-circulation platform, demonstrating no hyperacute rejection in a human lung transplantation model.
Development of a theranostic approach for ex vivo donor lung rehabilitation leveraging xenogeneic cross-circulation.
Funding received to support the development and clinical translation of bioengineered organs.
The company received a significant grant to advance treatments for fibrotic liver disease.
Funding to support research in cancer treatment applications.
Recognized for creating a new ingredient/technology or innovative use of an existing one in cosmetic products.